Injections of Tenoxicam or Meloxicam for TMJ Disc Displacement

Does Intra-articular Injection of Tenoxicam or Meloxicam After Arthrocentesis Affect Treatment Outcomes of Temporomandibular Joint Anterior Disc Displacement With Reduction? (A Randomized Controlled Trial)

This study is testing whether injections of Tenoxicam or Meloxicam can help people with TMJ disc displacement feel less pain and open their mouths more easily.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 45 Years
• Sex: All
• Sponsor: Beni-Suef University (Academic / other)
• Locations: 1 site (Banī Suwayf)
• Trial ID: NCT06403046 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effects of intra-articular injections of Tenoxicam or Meloxicam in patients with temporomandibular joint (TMJ) anterior disc displacement with reduction. The study aims to relieve symptoms such as pain and limited mouth opening by directly delivering these nonsteroidal anti-inflammatory drugs (NSAIDs) into the joint cavity. Participants will be assessed for their response to treatment, focusing on improvements in pain and joint function. The trial includes both Phase 1 and Phase 2 evaluations to determine safety and efficacy.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-45 with radiographic evidence of TMJ anterior disc displacement with reduction and associated symptoms.

Not a fit: Patients with disc displacement without reduction, osteoarthritis, or previous TMJ surgeries may not benefit from this treatment.

Why it matters

Potential benefit: If successful, this treatment could provide significant pain relief and improved function for patients suffering from TMJ disorders.

How similar studies have performed: Previous studies have shown that intra-articular injections of NSAIDs can be effective in managing TMJ disorders, suggesting a potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Patients of both sexes with an age range of 18-45 years.
2. Those patients with the radiographic interpretation of unilateral or bilateral (TMJ) anterior disc displacement with reduction with the clinical signs of pain, limitation of mouth opening, and TMJ clicking; Wilkes classification type II.

Exclusion Criteria:

1. Clinical or radiographic signs of disc displacement without reduction, osteoarthritis, or articular bony changes.
2. Previous (TMJ) surgery, arthrocentesis, or occlusal splints.
3. Any systemic disease affecting the temporomandibular joint's anatomy, mechanical function, or outcome of the proposed treatment.
4. Those Patients with a history of allergic reactions to any components of the injectable solutions.

Where this trial is running

Banī Suwayf

• Beni-suef university — Banī Suwayf, Egypt (Recruiting)

Study contacts

• Study coordinator: Ahmed N Alghandour, PHD

Conditions Temporomandibular Joint Disc Displacement, With Reduction